Literature DB >> 21115866

Lessons from the adjuvant bevacizumab trial on colon cancer: what next?

Eric Van Cutsem, Diether Lambrechts, Hans Prenen, Rakesh K Jain, Peter Carmeliet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21115866     DOI： 10.1200/JCO.2010.32.2701

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  40 in total

1.  Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Authors:  Robert W Ross; Matthew D Galsky; Phil Febbo; Marc Barry; Jerome P Richie; Wanling Xie; Fiona M Fennessy; Rupal S Bhatt; Julia Hayes; Toni K Choueiri; Clare M Tempany; Philip W Kantoff; Mary E Taplin; William K Oh
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

Review 3.  Challenges in the management of stage II colon cancer.

Authors:  Efrat Dotan; Steven J Cohen
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

Review 4.  Reappraising antiangiogenic therapy for breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

Review 5.  Rethinking the metastatic cascade as a therapeutic target.

Authors:  Lida A Mina; George W Sledge
Journal:  Nat Rev Clin Oncol       Date:  2011-04-19       Impact factor: 66.675

Review 6.  Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Authors:  John M L Ebos; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

7.  Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.

Authors:  Lee B Rivera; David Meyronet; Valérie Hervieu; Mitchell J Frederick; Emily Bergsland; Gabriele Bergers
Journal:  Cell Rep       Date:  2015-04-16       Impact factor: 9.423

Review 8.  Tumors: wounds that do not heal-redux.

Authors:  Harold F Dvorak
Journal:  Cancer Immunol Res       Date:  2015-01       Impact factor: 11.151

9.  Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype.

Authors:  Carmine Carbone; Tania Moccia; Cihui Zhu; Genni Paradiso; Alfredo Budillon; Paul J Chiao; James L Abbruzzese; Davide Melisi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

10.  Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.

Authors:  Motaz Qadan; Michael I D'Angelica
Journal:  Curr Colorectal Cancer Rep       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.